Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
May 9, 2023 11:08 AM EDT
Deals

Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

Max Gelman

Senior Editor

Am­gen is tak­ing a clos­er look at us­ing T cells for in­flam­ma­tion, an­nounc­ing a new deal Tues­day with TCR up­start TScan Ther­a­peu­tics.

The com­pa­nies will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roche no longer wants to be where ‘DNA se­quenc­ing goes to die’

Trump’s HHS de­fends drug price ne­go­ti­a­tions in No­var­tis suit

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Trump’s picks for NIH, CMS say they’ll un­load in­dus­try in­vest­ments

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times